Humoral immune response after different SARS-CoV-2 vaccination regimens | BMC Medicine | Full Text
Frontiers | Memory SARS-CoV-2 T-cell response in convalescent COVID-19 patients with undetectable specific IgG antibodies: a comparative study
Towards a population-based threshold of protection for COVID-19 vaccines - ScienceDirect
Evolution of antibody responses up to 13 months after SARS-CoV-2 infection and risk of reinfection - eBioMedicine
Antibody | Definition, Structure, Function, & Types | Britannica
Vaccines | Free Full-Text | Safety and Immunogenicity Following the Second and Third Doses of the BNT162b2 mRNA COVID-19 Vaccine in Adolescents with Juvenile-Onset Autoimmune Inflammatory Rheumatic Diseases: A Prospective Multicentre Study
Antibody - Wikipedia
Quantification of Severe Acute Respiratory Syndrome Coronavirus 2 Binding Antibody Levels To Assess Infection and Vaccine-Induced Immunity Using WHO Standards | Microbiology Spectrum
Principles for computational design of binding antibodies | PNAS
Anti‐SARS‐CoV‐2 IgG antibody levels among Thai healthcare providers receiving homologous and heterologous COVID‐19 vaccination regimens - Kittikraisak - 2022 - Influenza and Other Respiratory Viruses - Wiley Online Library
SARS-CoV-2 specific antibody and neutralization assays reveal the wide range of the humoral immune response to virus | Communications Biology
Real-world serological responses to extended-interval and heterologous COVID-19 mRNA vaccination in frail, older people (UNCoVER): an interim report from a prospective observational cohort study - The Lancet Healthy Longevity
Antibody signature induced by SARS-CoV-2 spike protein immunogens in rabbits | Science Translational Medicine
Frontiers | Protease-Activation of Fc-Masked Therapeutic Antibodies to Alleviate Off-Tumor Cytotoxicity
GP-specific binding antibody responses (ELISA units/mL): Regimen profiles (geometric means with 95% CIs); immunogenicity analysis set.
Diagnostics | Free Full-Text | Evaluation of Anti-SARS-Cov-2 S-RBD IgG Antibodies after COVID-19 mRNA BNT162b2 Vaccine
A panel of human neutralizing mAbs targeting SARS-CoV-2 spike at multiple epitopes | Nature Communications
Anti-Spike protein assays to determine post-vaccination antibody levels: a head-to-head comparison of five quantitative assays | medRxiv
The smallest functional antibody fragment: Ultralong CDR H3 antibody knob regions potently neutralize SARS-CoV-2 | PNAS
Course of binding antibody units per milliliter (BAU/mL) ratio of... | Download Scientific Diagram
Dynamics of SARS-CoV-2 neutralising antibody responses and duration of immunity: a longitudinal study - The Lancet Microbe
Groups identified by multi-IgG-ACE2-RBD correspond to defined ranges of... | Download Scientific Diagram
Kinetics of naturally induced binding and neutralizing anti-SARS-CoV-2 antibody levels and potencies among Kenyan patients with diverse grades of COVID-19 severity | medRxiv
Antibody - Wikipedia
Correlates of protection against symptomatic and asymptomatic SARS-CoV-2 infection | Nature Medicine
SARS-CoV-2 Convalescent Sera Binding and Neutralizing Antibody Concentrations Compared with COVID-19 Vaccine Efficacy Estimates against Symptomatic Infection | Microbiology Spectrum
